Table of contents
March 2005 Volume 2 No 3
Editorial
Viewpoint
Breast pathology: rationale for adopting the ductal intraepithelial neoplasia (DIN) classification
116This Viewpoint advocates a radical rehaul of the system for describing breast pathology, to echo the classification systems used in other organs. Molecular alterations detected by comparative genomic hybridization highlight some of the deficiencies of the current system for differentiation of different types of breast tumors.
Research Highlights
Adjuvant CMF in breast cancer: 30 years' experience
118Reduced breast cancer mortality in Copenhagen screening program
118Colorectal cancer survival among European and US patients
118Defining risk in patients with renal-cell carcinoma
119Gene-expression profiling to predict cancer outcome
120Role of KRAS in determining response to gefitinib or erlotinib
121Unstable DNA in cells obtained by prostatic massage associated with cancer
122Is fine-needle aspiration safe in patients with small HCC?
122Treating esophageal cancer in gastrectomized patients
123Practice Points
What are the risk factors for brain metastasis in breast cancer patients?
124Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
126How reliable is MRI for predicting extent of residual breast cancer with different primary medical therapies?
128Do we need to improve pain management in the radiation oncology department?
130Can molecular markers predict local, regional and distant metastasis in head and neck cancer?
132Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers?
134Reviews
Technology Insight: applications of emerging immunotherapeutic strategies for Epstein–Barr virus-associated malignancies
138Epstein–Barr virus (EBV)-associated malignancies are a heterogenous group of tumors that are generally relatively radiosensitive and chemosensitive in their early stages, but less amenable to conventional modality therapy in late stage or relapse. New and emerging strategies to manipulate the immune response are discussed. These strategies are used either alone or as an adjuvant therapy in combination with chemotherapy with or without monoclonal antibodies.
doi:10.1038/ncponc0107 | Full Text | PDF (543K)
Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid
150Histone deacetylase inhibitors show significant activity against a broad spectrum of neoplasms, at doses that are well tolerated by cancer patients. These molecules control post-translational modification of histones, which is an important epigenetic regulation of gene expression. The discovery and development of suberoylanilide hydroxamic acid (SAHA), which is one of the most advanced compounds in this group, is the focus of this review.
doi:10.1038/ncponc0106 | Full Text | PDF (490K)
Therapy Insight: cancer anorexia–cachexia syndrome—when all you can eat is yourself
158Quality-of-life improvements and nutritional status are important in the management of cancer patients, but are often overlooked. Treatments for anorexia and cachexia are often attempted during the advanced stages of the disease. Cytokines and tumor-derived factors appear have a significant role in the pathogenesis of anorexia and cachexia. Laviano et al. discuss the pathogenesis and diagnosis of cachexia and anorexia, focusing on the dietary and drug interventions, which can prolong survival and positively influence quality of life for cancer patients.
doi:10.1038/ncponc0112 | Full Text | PDF (202K)
Case Study
Multiple gastrointestinal stromal tumors and synchronous ileal carcinoids
166doi:10.1038/ncponc0108 | Full Text | PDF (425K)
